Skip to main content
Shanghai Haoyuan Chemexpress Co.,Ltd. logo

Shanghai Haoyuan Chemexpress Co.,Ltd. — Investor Relations & Filings

Ticker · 688131 ISIN · CNE1000051J4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,015 across all filing types
Latest filing 2026-05-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688131

About Shanghai Haoyuan Chemexpress Co.,Ltd.

https://www.chemexpress.com/

Shanghai Haoyuan Chemexpress Co., Ltd., also known as ChemExpress, specializes in the research, development, and manufacturing of high-end chemical building blocks and active pharmaceutical ingredients. The company operates as a provider of integrated services, including custom synthesis, process development, and large-scale production. Its core product offerings feature a comprehensive library of small molecule building blocks, specialized linkers for antibody-drug conjugates, and chemical tools for targeted protein degradation. ChemExpress serves a global client base of research institutions and biotechnology firms, supporting the drug discovery and development pipeline from initial laboratory research through to commercial-scale manufacturing. The organization focuses on delivering high-purity chemical components and technical expertise to facilitate complex molecular synthesis and optimization.

Recent filings

Filing Released Lang Actions
上海皓元医药股份有限公司向不特定对象发行可转换公司债券2026年第一次临时受托管理事务报告
Capital/Financing Update Classification · 63% confidence The document is a detailed interim trustee management report regarding the 2026 issuance and ongoing management of Shanghai Haoyuan Pharmaceutical’s convertible bonds. It covers bond terms, issuance approvals, trustee responsibilities, event triggers, and adjustments to the use of proceeds. This is not an earnings release, management discussion, or audit report, nor is it simply an announcement of a report. Instead, it is a substantive update on the company’s financing activity (the convertible bond issuance and trust management), fitting the definition of a Capital/Financing Update (CAP).
2026-05-28 Chinese
德恒上海律师事务所关于上海皓元医药股份有限公司2025年年度股东会之见证法律意见书
Regulatory Filings Classification · 80% confidence The document is a legal opinion (“见证法律意见书”) issued by the company’s law firm concerning the convening, procedural compliance, and voting results of the 2025 Annual General Meeting. It is not the company’s own AGM presentation material (AGM-R), proxy solicitation (PSI), or a standalone vote-results announcement (DVA). Instead, it serves as a compliance/legal attestation (an external counsel’s certification letter) required for regulatory purposes. Under the Certification Rule, such legal opinion/attestation letters fall under Regulatory Filings (RNS).
2026-05-28 Chinese
上海皓元医药股份有限公司关于“皓元转债”可选择回售的公告
Capital/Financing Update Classification · 87% confidence The document is an official corporate announcement detailing the terms, timeline, and procedures for bondholders’ optional put (回售) of the company’s convertible bonds (“皓元转债”). It specifies repurchase price, period, payment date, trading suspension rules, and procedural steps. This constitutes a financing/capital structure event (redeeming convertible debt). It is not a general regulatory or report publication announcement nor an annual or interim report. Therefore, it falls under Capital/Financing Update.
2026-05-28 Chinese
德恒上海律师事务所关于上海皓元医药股份有限公司“皓元转债”2026年第一次债券持有人会议之法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter (法律意见书) prepared by a law firm for the 2026 first bondholders’ meeting of Shanghai Haoyuan Pharmaceutical Co., Ltd.’s convertible bonds. It does not present financial results (so not 10-K, IR, ER, etc.), nor is it a proxy or investor presentation. It also is not an AGM shareholder vote announcement (it’s a bondholders’ meeting). It serves as a compliance/legal filing accompanying the bondholder meeting and thus falls under miscellaneous regulatory compliance filings. Accordingly, it best fits the Regulatory Filings category (RNS).
2026-05-28 Chinese
上海皓元医药股份有限公司关于股东冻结股份被动减持计划公告
Regulatory Filings Classification · 80% confidence The document is a formal disclosure by Shanghai Haoyuan Medical Co. Ltd. concerning a shareholder’s passive share reduction plan (量化减持计划公告) due to judicial enforcement. It details shareholding amounts, planned reduction volumes, timing, legal basis, and regulatory commitments. This is not an earnings release, financial report, proxy, or merger filing, nor a company buyback of treasury stock. Rather, it is a regulatory announcement about share disposition by a shareholder. Therefore it best fits the Regulatory Filings (RNS) category.
2026-05-24 Chinese
上海皓元医药股份有限公司2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled “2025年年度股东会会议资料” and comprises meeting materials for the 2025 annual shareholders’ meeting, including meeting notices, agenda, proposals, and related governance documents. It is not a financial report itself (10-K/IR) nor merely an announcement, but the actual AGM presentation materials. It therefore fits the definition of AGM Information (AGM-R).
2026-05-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.